[{"id":"ca7e4b34-6f76-4ea3-8c6b-e39973324752","acronym":"NRG-LU003","url":"https://clinicaltrials.gov/study/NCT03737994","created_at":"2023-11-21T21:15:46.432Z","updated_at":"2025-02-25T12:37:11.248Z","phase":"Phase 2","brief_title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03737994 - NRG-LU003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" ALK positive • MET amplification • ALK rearrangement","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • MET amplification • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/25/2019","start_date":" 07/25/2019","primary_txt":" Primary completion: 07/21/2021","primary_completion_date":" 07/21/2021","study_txt":" Completion: 12/02/2025","study_completion_date":" 12/02/2025","last_update_posted":"2025-02-24"},{"id":"52814cd1-a8ab-4fbc-9958-b65faef07451","acronym":"","url":"https://clinicaltrials.gov/study/NCT05599412","created_at":"2022-10-31T13:56:49.808Z","updated_at":"2025-02-25T14:41:38.018Z","phase":"","brief_title":"Post Marketing Surveillance(PMS) Study of Lorviqua in Korea","source_id_and_acronym":"NCT05599412","lead_sponsor":"Pfizer","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2025-02-14"},{"id":"4b1b80e8-bcd8-4a78-8ae1-fe238c0362b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126916","created_at":"2021-01-18T15:24:54.957Z","updated_at":"2025-02-25T15:10:35.328Z","phase":"Phase 3","brief_title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","source_id_and_acronym":"NCT03126916","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 724","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-13"},{"id":"f032cb75-7b0a-4fb8-9e69-7cf2c851ab56","acronym":"COMLORLA","url":"https://clinicaltrials.gov/study/NCT06690541","created_at":"2025-02-26T13:54:01.529Z","updated_at":"2025-02-26T13:54:01.529Z","phase":"","brief_title":"Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC","source_id_and_acronym":"NCT06690541 - COMLORLA","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/10/2024","start_date":" 11/10/2024","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 10/31/2030","study_completion_date":" 10/31/2030","last_update_posted":"2024-11-15"},{"id":"55fca2cd-0dc1-47d8-86f5-df409157addc","acronym":"ALKALINE","url":"https://clinicaltrials.gov/study/NCT04127110","created_at":"2021-01-18T20:09:41.572Z","updated_at":"2025-02-25T12:37:27.279Z","phase":"Phase 2","brief_title":"Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients","source_id_and_acronym":"NCT04127110 - ALKALINE","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 11/17/2020","start_date":" 11/17/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-11-05"},{"id":"59529bbb-f615-4981-937f-6ac29b7ec1c3","acronym":"PIKACHU","url":"https://clinicaltrials.gov/study/NCT04322890","created_at":"2021-01-18T20:56:40.742Z","updated_at":"2024-07-02T16:34:59.292Z","phase":"Phase 2","brief_title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","source_id_and_acronym":"NCT04322890 - PIKACHU","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2027","study_completion_date":" 12/24/2027","last_update_posted":"2024-06-04"},{"id":"8d11e7de-5fd7-49f6-b0e9-31e7346e7fd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04800822","created_at":"2021-03-16T14:52:26.431Z","updated_at":"2024-07-02T16:35:06.982Z","phase":"Phase 1","brief_title":"PF-07284892 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT04800822","lead_sponsor":"Pfizer","biomarkers":" ALK • ROS1 • NF1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive","tags":["ALK • ROS1 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 06/18/2024","primary_completion_date":" 06/18/2024","study_txt":" Completion: 11/29/2025","study_completion_date":" 11/29/2025","last_update_posted":"2024-04-30"},{"id":"a6c847c7-a1bd-4b36-aa8d-0987c59a806b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04979988","created_at":"2021-07-28T19:52:27.204Z","updated_at":"2024-07-02T16:35:11.225Z","phase":"","brief_title":"Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients","source_id_and_acronym":"NCT04979988","lead_sponsor":"Pfizer","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alecensa (alectinib) • Lorbrena (lorlatinib)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 12/09/2021","primary_completion_date":" 12/09/2021","study_txt":" Completion: 12/09/2021","study_completion_date":" 12/09/2021","last_update_posted":"2024-04-05"},{"id":"5452d7d5-025f-4999-aea4-518221d84eaf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04362072","created_at":"2021-01-18T21:05:08.971Z","updated_at":"2024-07-02T16:35:15.535Z","phase":"Phase 4","brief_title":"Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04362072","lead_sponsor":"Pfizer","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 09/29/2020","start_date":" 09/29/2020","primary_txt":" Primary completion: 06/25/2024","primary_completion_date":" 06/25/2024","study_txt":" Completion: 06/25/2024","study_completion_date":" 06/25/2024","last_update_posted":"2024-03-08"},{"id":"6e624d98-871e-49ea-8880-cb9fc71ea587","acronym":"ORAKLE","url":"https://clinicaltrials.gov/study/NCT04111705","created_at":"2021-01-18T20:06:14.100Z","updated_at":"2024-07-02T16:35:15.855Z","phase":"Phase 2","brief_title":"Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04111705 - ORAKLE","lead_sponsor":"Intergroupe Francophone de Cancerologie Thoracique","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 08/05/2020","start_date":" 08/05/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-07"},{"id":"572a4851-2844-4d71-983a-e125903b898b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06282991","created_at":"2024-02-28T22:32:48.726Z","updated_at":"2024-07-02T16:35:17.489Z","phase":"","brief_title":"A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled","source_id_and_acronym":"NCT06282991","lead_sponsor":"Pfizer","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 07/22/2020","start_date":" 07/22/2020","primary_txt":" Primary completion: 01/18/2021","primary_completion_date":" 01/18/2021","study_txt":" Completion: 01/18/2021","study_completion_date":" 01/18/2021","last_update_posted":"2024-02-28"},{"id":"608c0d3a-2362-4472-ad82-9dd04e9005a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03909971","created_at":"2021-01-18T19:14:43.723Z","updated_at":"2024-07-02T16:35:18.353Z","phase":"Phase 2","brief_title":"A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China","source_id_and_acronym":"NCT03909971","lead_sponsor":"Pfizer","biomarkers":" EML4","pipe":" | ","alterations":" ALK positive • EML4-ALK fusion • ALK fusion","tags":["EML4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • EML4-ALK fusion • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 04/28/2019","start_date":" 04/28/2019","primary_txt":" Primary completion: 08/10/2020","primary_completion_date":" 08/10/2020","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-21"},{"id":"0a7338b3-c7e0-4adc-a08e-32331313e99f","acronym":"CROWN","url":"https://clinicaltrials.gov/study/NCT03052608","created_at":"2021-01-17T17:11:23.914Z","updated_at":"2024-07-02T16:35:18.492Z","phase":"Phase 3","brief_title":"A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC","source_id_and_acronym":"NCT03052608 - CROWN","lead_sponsor":"Pfizer","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Lorbrena (lorlatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 296","initiation":"Initiation: 04/27/2017","start_date":" 04/27/2017","primary_txt":" Primary completion: 03/20/2020","primary_completion_date":" 03/20/2020","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-02-20"},{"id":"14b0ab67-5750-41ae-9f57-7535c1590a2a","acronym":"GALILEO","url":"https://clinicaltrials.gov/study/NCT06234579","created_at":"2024-01-31T23:19:42.835Z","updated_at":"2024-07-02T16:35:21.449Z","phase":"","brief_title":"Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)","source_id_and_acronym":"NCT06234579 - GALILEO","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alecensa (alectinib) • Lorbrena (lorlatinib) • Alunbrig (brigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 07/12/2021","start_date":" 07/12/2021","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-01-31"},{"id":"6d847628-818f-4e1d-8da1-c3a365e4c09c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04621188","created_at":"2021-01-19T20:34:31.159Z","updated_at":"2024-07-02T16:35:25.732Z","phase":"Phase 2","brief_title":"Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)","source_id_and_acronym":"NCT04621188","lead_sponsor":"Intergroupe Francophone de Cancerologie Thoracique","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 rearrangement","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 03/19/2021","start_date":" 03/19/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-12-19"},{"id":"aac22bf1-a2a4-4a36-8573-d98dcca7d564","acronym":"","url":"https://clinicaltrials.gov/study/NCT06092086","created_at":"2023-10-23T20:13:37.760Z","updated_at":"2024-07-02T16:35:32.314Z","phase":"Phase 2","brief_title":"Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC","source_id_and_acronym":"NCT06092086","lead_sponsor":"Guangdong Association of Clinical Trials","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement • ALK mutation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 08/18/2023","start_date":" 08/18/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2030","study_completion_date":" 08/01/2030","last_update_posted":"2023-10-20"},{"id":"bc442fae-5277-4af0-8cfb-b533377db250","acronym":"","url":"https://clinicaltrials.gov/study/NCT06007937","created_at":"2023-08-23T15:11:08.742Z","updated_at":"2024-07-02T16:35:39.290Z","phase":"Phase 1/2","brief_title":"A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer","source_id_and_acronym":"NCT06007937","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ALK","pipe":" | ","alterations":" ALK fusion","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib) • Cyramza (ramucirumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/17/2023","start_date":" 08/17/2023","primary_txt":" Primary completion: 08/17/2028","primary_completion_date":" 08/17/2028","study_txt":" Completion: 08/17/2028","study_completion_date":" 08/17/2028","last_update_posted":"2023-08-23"},{"id":"9cf95299-337e-4793-9854-4e20648d3329","acronym":"CRU3","url":"https://clinicaltrials.gov/study/NCT03505554","created_at":"2021-01-18T17:15:28.396Z","updated_at":"2024-07-02T16:35:40.815Z","phase":"Phase 2","brief_title":"A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma","source_id_and_acronym":"NCT03505554 - CRU3","lead_sponsor":"University of Milano Bicocca","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/10/2017","start_date":" 10/10/2017","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-08-07"},{"id":"5f9804b9-88fc-46a5-bcd4-30a909e6dda8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01970865","created_at":"2021-01-17T17:11:22.323Z","updated_at":"2024-07-02T16:35:46.223Z","phase":"Phase 1/2","brief_title":"A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations","source_id_and_acronym":"NCT01970865","lead_sponsor":"Pfizer","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement • ALK mutation • ROS1 positive • ROS1 rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement • ALK mutation • ROS1 positive • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Lorbrena (lorlatinib)"],"overall_status":"Completed","enrollment":" Enrollment 334","initiation":"Initiation: 01/08/2014","start_date":" 01/08/2014","primary_txt":" Primary completion: 03/15/2017","primary_completion_date":" 03/15/2017","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2023-06-07"},{"id":"1427eec4-ad27-4c77-af5b-007ed81dc9bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04541407","created_at":"2021-01-18T21:43:42.871Z","updated_at":"2024-07-02T16:35:47.920Z","phase":"Phase 1","brief_title":"Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease","source_id_and_acronym":"NCT04541407","lead_sponsor":"University of Colorado, Denver","biomarkers":" ALK","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L858R + EGFR exon 21 deletion","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L858R + EGFR exon 21 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • temozolomide • Lorbrena (lorlatinib)"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 10/29/2020","start_date":" 10/29/2020","primary_txt":" Primary completion: 04/25/2022","primary_completion_date":" 04/25/2022","study_txt":" Completion: 06/07/2022","study_completion_date":" 06/07/2022","last_update_posted":"2023-05-16"},{"id":"033e0de5-abbe-405f-9838-dbe4dfe367ae","acronym":"LORLAPULM","url":"https://clinicaltrials.gov/study/NCT05167500","created_at":"2021-12-22T19:15:18.383Z","updated_at":"2024-07-02T16:35:51.879Z","phase":"","brief_title":"Efficacy \u0026 Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment","source_id_and_acronym":"NCT05167500 - LORLAPULM","lead_sponsor":"Fundación GECP","biomarkers":" ALK • ROS1","pipe":"","alterations":" ","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Completed","enrollment":" Enrollment 118","initiation":"Initiation: 12/09/2021","start_date":" 12/09/2021","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2023-03-30"},{"id":"4295deb0-8b42-475f-a849-f72251e7e309","acronym":"","url":"https://clinicaltrials.gov/study/NCT04541706","created_at":"2021-01-18T21:43:46.247Z","updated_at":"2024-07-02T16:36:03.976Z","phase":"Phase 4","brief_title":"Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India","source_id_and_acronym":"NCT04541706","lead_sponsor":"Pfizer","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 08/27/2020","start_date":" 08/27/2020","primary_txt":" Primary completion: 07/20/2022","primary_completion_date":" 07/20/2022","study_txt":" Completion: 07/20/2022","study_completion_date":" 07/20/2022","last_update_posted":"2022-09-14"},{"id":"8e988c26-8dc2-4194-920c-8c9efc8fb89e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03612154","created_at":"2021-01-18T17:45:16.161Z","updated_at":"2024-07-02T16:36:13.921Z","phase":"Phase 2","brief_title":"Study of Lorlatinib in ROS1 Rearranged NSCLC","source_id_and_acronym":"NCT03612154","lead_sponsor":"National Cancer Center, Korea","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 rearrangement","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 05/02/2019","start_date":" 05/02/2019","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-04-06"},{"id":"fd217827-ebf7-48be-9274-6e6e332365a1","acronym":"PFROST","url":"https://clinicaltrials.gov/study/NCT03439215","created_at":"2021-01-18T16:57:49.420Z","updated_at":"2024-07-02T16:36:27.767Z","phase":"Phase 2","brief_title":"PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer","source_id_and_acronym":"NCT03439215 - PFROST","lead_sponsor":"Fondazione Ricerca Traslazionale","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 rearrangement","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Lorbrena (lorlatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/13/2017","start_date":" 06/13/2017","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2021-07-19"}]